← Leaderboards
Maurizio Chiriva-Internati
Mandalmed, Inc.
$831,918
Attributed
$1,663,836
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $852.5K · FY2008–18$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,663,836 · 4
By mechanism
R42$850,531 · 1
R41$449,369 · 2
R43$363,936 · 1
Top collaborators
- Martin J. D'Souza2 shared
- Leonardo Mirandola2 shared
- Constance M John1 shared
- George E Taffet1 shared
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventMouse ModelProteinsBaseTumorRegulatory T-LymphocyteMediatingPre-ClinicalSerumResponseLigandsImmune SystemCancer CellLifeNeoplastic CellAntibodiesT-LymphocyteDendritic CellsCytotoxic T-LymphocytesImmunityCytokineAnimalsAffectImmunogenic
Grant awards (6)
Development and non-clinical GLP testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors.$850,531
R42 · FY2018 · HL · contact PI
Microparticulate mucosal vaccine for triple-negative breast cancer$2,000
R41 · FY2018 · CA
Microparticulate mucosal vaccine for triple-negative breast cancer$224,522
R41 · FY2017 · CA
Ovarian cancer using novel nanoparticle formulations$101,844
R41 · FY2015 · CA · contact PI
Ovarian cancer using novel nanoparticle formulations$121,003
R41 · FY2014 · CA · contact PI
Preclinical Testing of Galectin-3C for Multiple Myeloma$363,936
R43 · FY2008 · CA